Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

In a randomized, head-to-head, placebo-controlled trial, we enrolled adults with obesity (body-mass index [the weight in kilograms divided by the square of height meters], 32 to 43) who did not have diabetes. After an 8-week low-calorie diet, participants were randomly assigned for 1 year one four strategies: moderate-to-vigorous–intensity exercise program plus placebo (exercise group); treatment liraglutide (3.0 mg per day) usual activity (liraglutide therapy (combination or (placebo group). End points prespecified hypotheses change body (primary end point) and body-fat percentage (secondary from randomization period intention-to-treat population. Prespecified metabolic health-related safety also assessed.